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LETTER TO THE EDITOR
Intrauterine parvovirus B19 infection: early pre-
natal diagnosis is possible
Human parvovirus B19 infection occurs commonly
in childhood and is also found in previously seroneg-
ative adults. The prevalence of B19 seropositivity
amongst adults is between 40—60%1,2 and is be-
tween 35—55% in pregnant women.
Women of childbearing age in the USA show an
annual seroconversion rate of 1.5%.3 Transplacen-
tal transmission of parvovirus B19 to the fetus may
be common following maternal infection. A large
prospective study on 193 cases of conﬁrmed B19
infection in pregnancy estimated that the fetal
infection rate was 33%, and found a risk of non-
immune hydrops fetalis and of fetal mortality of
around 9%.4,5 Moreover, sporadic cases of meco-
nium peritonitis in hydropic fetuses have been
reported.6 However, it is not yet known whether
some congenital abnormalities, such as ocular ab-
normalities and central nervous system abnormal-
ities, are correlated with parvovirus B19 infection
during pregnancy.7,8
During an outbreak of erythema infectiosum in
Florence in the spring of 2002, a 37-year-old preg-
nant woman developed an erythema infectiosum in
the 14th week of gestation. Maternal serum proved
positive for anti-parvovirus B19 IgM and IgG (Parvo
IgM and Parvo IgG EIA, Seiken, Tokyo, Japan) as
well as for B19 DNA sequences by a nested poly-
merase chain reaction (PCR); this reaction ampli-
ﬁes B19 DNA sequences in the region coding for the
NS1 protein, as already described.9 Amniotic ﬂuid
collected two weeks after the onset of the rash was
positive for B19 DNA by PCR. As maternal infection
with parvovirus B19 is now recognized as a poten-
tial risk for adverse pregnancy outcome, especially
during the ﬁrst 20 weeks of pregnancy, ultrasound
monitoring was performed and no fetal abnormality
was observed. At 36 weeks, a boy of 4.6 kg was born,
with Apgar scores of 7 and 8 at one and ﬁve min-
utes respectively, with normal hematological data
and without any other abnormalities (echocardiog-
raphy, cranial ultrasound and chest X-ray were nor-
mal). B19 DNA was absent in the newborn serum.
As far as we know, there are no data about the
reliability of the nested PCR performed on amni-
otic ﬂuid with regard to (1) gestational age and (2)
the interval betweenmaternal infection and amnio-
centesis. In this case, nested PCR on amniotic ﬂuid
was found positive at the 16th week of gestation,
only two weeks after the onset of erythema infec-
tiosum. We therefore believe that prenatal diagno-
sis of parvovirus B19 infection may be performed
earlier compared to varicella, toxoplasmosis and
cytomegalovirus infection, where the best results
are achieved when amniotic ﬂuid is taken after 18
weeks (21 weeks for cytomegalovirus) of gestation
and 4—6 weeks after onset of maternal disease (6—
9 weeks for cytomegalovirus).
Additionally in our case, B19 DNA levels were low,
only detectable by a qualitative PCR, being under
the sensitivity of the real time quantitative PCR
used, either in maternal serum or in amniotic ﬂuid.
B19 DNA was negative in newborn serum. It is pos-
sible that a mild fetal infection was easily cleared
before birth. More observations are required in or-
der to assess the prognostic value of a quantita-
tive detection of B19 DNA in maternal serum and
amniotic ﬂuid. We suggest that prenatal diagnosis
(preferably early) could be useful because the real
risk of congenital abnormalities connected to par-
vovirus B19 is unknown at this time and because
many terminations of pregnancy, made for this rea-
son, could be avoided.
Finally, this observation suggests that the perfor-
mance of B19 infection diagnosis on maternal and
newborn blood could lead to an underestimation of
intrauterine B19 infection rate.
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